With regard to Health Canada’s approval of the COVID-19 modRNA vaccines (modified with N1-methylpseudouridine) for pregnant women: (a) what specific research data supported the claims that (i) this product may be safely administered at any stage of pregnancy, (ii) this product protects pregnant women from SARS-CoV-2 infection and severe disease, (iii) the vaccinated mother is less likely to transmit SARS-CoV-2 to her newborn after delivery compared to an unvaccinated mother, (iv) the modRNA vaccine, and consequently the spike protein, do not excrete into breast milk, (v) the modRNA, and consequently the spike protein, do not cross the placental barrier, (vi) all modRNA is destroyed in the human body within about two days, (vii) there is no possibility that the modRNA vaccine contents will enter the cell nucleus and modify the human genome; (b) with respect to the claims in (a), has Heath Canada modified these claims based on updated scientific research, and if so, which claims and how; (c) what is the real-world data indicating that this product presents no safety concerns for the pregnant woman or the developing fetus or newborn; (d) what is the quantitative threshold for a concerning safety signal for these cohorts; (e) how has the monograph for the COVID-19 modRNA vaccines been updated in relation to pregnancy and lactation to convey this safety research data; and (f) when were these updates made?
In the House of Commons on April 10th, 2024. See this statement in context.